Literature DB >> 20359636

Myelodysplastic syndromes classification and risk stratification.

Rami S Komrokji1, Ling Zhang, John M Bennett.   

Abstract

Myelodysplastic syndromes (MDS) are spectrum of bone marrow failure disorders that share a common pathologic feature: cytologic dysplasia. The classification of MDS reflects the understanding of the disease. It is hoped that in the future classification and risk stratification will be based on underlying pathobiology of different disease subsets and molecular signatures where the pathologic classification represents their phenotype. This article reviews MDS classification and risk stratification highlighting differences between the various systems. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20359636     DOI: 10.1016/j.hoc.2010.02.004

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  17 in total

Review 1.  Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis.

Authors:  Yeong-Hau H Lien; Li-Wen Lai
Journal:  Nat Rev Nephrol       Date:  2010-12-14       Impact factor: 28.314

2.  Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes.

Authors:  Rami S Komrokji; Eric Padron; Daohai Yu; William J Fulp; Yuraima Rodriguez; Sara Tinsley; Alan F List; Jeffrey E Lancet
Journal:  Am J Hematol       Date:  2014-05-16       Impact factor: 10.047

3.  Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes.

Authors:  Eric Padron; Markus C Ball; Jamie K Teer; Jeffrey S Painter; Sean J Yoder; Chaomei Zhang; Ling Zhang; Lynn C Moscinski; Dana E Rollison; Steven D Gore; Rafael Bejar; Matthew J Walter; Mikkael A Sekeres; Rami S Komrokji; Pearlie K Epling-Burnette
Journal:  Blood       Date:  2018-04-16       Impact factor: 22.113

Review 4.  Telomere biology in hematopoiesis and stem cell transplantation.

Authors:  Shahinaz M Gadalla; Sharon A Savage
Journal:  Blood Rev       Date:  2011-07-20       Impact factor: 8.250

5.  Cost of the treatment of myelodisplastic syndrome in Brazil.

Authors:  Otávio Clark; Enéas José de Matos Faleiros
Journal:  Rev Bras Hematol Hemoter       Date:  2011

6.  Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.

Authors:  Dana E Rollison; Kenneth H Shain; Ji-Hyun Lee; Shalaka S Hampras; William Fulp; Kate Fisher; Najla H Al Ali; Eric Padron; Jeffrey Lancet; Qiang Xu; Martha Olesnyckyj; Laurie Kenvin; Robert Knight; William Dalton; Alan List; Rami S Komrokji
Journal:  Cancer Med       Date:  2016-04-20       Impact factor: 4.452

7.  Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.

Authors:  Asmita Mishra; Maria Corrales-Yepez; Najla Al Ali; Mohamed Kharfan-Dabaja; Eric Padron; Ling Zhang; Pearlie K Epling-Burnette; Javier Pinilla-Ibarz; Jeffrey E Lancet; Alan F List; Rami S Komrokji
Journal:  Am J Hematol       Date:  2013-05-30       Impact factor: 10.047

Review 8.  Myelodysplastic syndromes and autoimmune diseases--case series and review of literature.

Authors:  Omar Al Ustwani; Laurie A Ford; Sheila J N Sait; Anne Marie W Block; Maurice Barcos; Carlos E Vigil; Elizabeth A Griffiths; James E Thompson; Eunice S Wang; Julian Ambrus; Meir Wetzler
Journal:  Leuk Res       Date:  2013-05-18       Impact factor: 3.156

Review 9.  The myelodysplastic syndrome as a prototypical epigenetic disease.

Authors:  Jean-Pierre J Issa
Journal:  Blood       Date:  2013-05-09       Impact factor: 22.113

10.  An association between hypoplastic myelodysplastic syndrome and T-prolymphocytic leukaemia.

Authors:  C A Arathi; K R Puttaraj; S N Shobha
Journal:  J Lab Physicians       Date:  2011-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.